Hints and tips:
Related Special Reports
Related Topics
...But the companies do not have a history of protein manufacturing used by Novo Nordisk and its US rival Eli Lilly to make their diabetes and weight-loss products....
...The success of the Danish pharma group’s blockbuster weight-loss drugs helped it book record sales last year, pushing it to a $500bn market capitalisation....
...Eli Lilly’s weight-loss drug tirzepatide significantly reduced sleep apnoea problems in a late-stage clinical trial, the pharmaceutical group said on Wednesday, adding to evidence that could encourage more...
...Sistani made waves in the weight management industry last year with an acquisition that took the company Jean Nidetch launched in 1963 to run weight-loss support groups into the business of dispensing anti-obesity...
...Some users of Medicare, the US government-funded insurance programme for seniors, will be able to access weight-loss drugs if they suffer from certain conditions such as cardiovascular disease, officials...
...The company’s amycretin oral pill — which has a different formulation to its popular diabetes and weight loss medicines Ozempic and Wegovy — resulted in a 13 per cent weight loss in early stage trials....
...In February’s mid-stage trials, Eli Lilly’s weight loss drug tirzepatide showed promise against MASH....
...Patients on average can expect to lose about 12 to 15 per cent of their body weight when using the drugs....
...Typically, GLP-1 users regain all the weight they lost after discontinuing the treatment. Aardvark and Cantor Fitzgerald declined to comment....
...Novo Nordisk’s blockbuster weight loss drugs powered the company to record a 36 per cent increase in sales last year....
...Demand for weight-loss solutions is high in China, where obesity rates among Chinese adults have also more than doubled in less than two decades....
...Clip from Lionsgate Television For further reading: WeightWatchers faces an era when weight loss comes in a syringe Behold the Ozempic effect on business The race to develop the next generation of weight-loss...
...To do this, the company has launched trials of its weight-loss treatments to show that they can also tackle diseases linked to obesity....
...and challenging the 21 per cent average weight loss of Zepbound....
...and dramatic weight-loss results boosting demand....
...Senior British diplomats say he has brought “weight and heft” to the Foreign Office, paying tribute to his work ethic and arguing that he has injected fresh confidence and ideas into British foreign policy...
...It looked at height and weight measurements for people aged five and older, using it to calculate body mass index and estimate obesity and underweight rates....
...Novo Nordisk’s weight-loss drug Wegovy cut the risk of death by 18 per cent in trial results announced in November, with a 28 per cent fall in the risk of heart attacks....
...And weight loss drugs like Ozempic have been in the news a lot. But are we missing their true potential?...
...Huge demand for GLP-1s, the lucrative new class of diabetes and weight-loss drugs that include Wegovy and Zepbound, is testing the capacity of plants capable of the formulation of pharmaceutical solutions...
...But healthcare providers must also decide whether weight-loss drugs represent value for money....
...The US pharma group was, perhaps, just trying to get ahead of the inevitable attention that weight-loss medicines would receive amid the Oscars glitz....
FT Person of the Year reflects on how the obesity medications have changed the way we think about diets
International Edition